Abstract 2640
Background
S-TRAC, a prospective phase 3 randomized trial in pts with resected RCC at high risk for recurrence, demonstrated a statistically significant improvement in DFS with sunitinib (SU) vs placebo; HR 0.76; 95% CI: 0.59, 0.98; P = 0.03. We hypothesized that DFS is a surrogate for OS and evaluated the association of DFS events with OS.
Methods
DFS (by blinded independent review) was defined from randomization to first evidence of recurrence, second primary malignancy, or death, whichever occurred first. Pts were categorized as having DFS or censored ≤2 years vs DFS >2 years, and as having OS or censored ≤5 years vs OS > 5 years. The odds ratio (OR), positive predictive values (PPV) and negative PV (NPV) were reported. To determine if DFS can be a surrogate for OS, 2 conditions need to be tested: 1) DFS and OS are strongly correlated, and 2) the treatment effect on DFS is sufficiently correlated with the effect on OS. The validity of the surrogate is reflected by the strength of these correlations. The correlation between DFS and OS is tested at the pt level through copula models to estimate the correlation coefficient (Kendall τ). Trial level correlations have been explored considering region as the trial unit.
Results
Median follow-up for OS was approximately 6.5 years with 141 (23%) observed deaths. There were 257 (42%) DFS events. Of 261 pts with DFS or censored ≤2 years of enrollment, 97 were alive and in follow-up >5 years (37%). In 354 pts with DFS >2 years, 318 pts were alive >5 years (90%). The OR, PPV and NPV were 14.9, 0.9 and 0.63, respectively. Kendall’s τ ranged from 0.51 to 0.88 using the Hougaard, Clayton, and Plackett copula, suggesting a moderate correlation at the individual pt level. Similar results were observed with investigator assessed DFS. Analyses of trial level correlations also suggest a moderate correlation. Further analyses are being explored.
Conclusions
A moderate correlation between DFS and OS was observed in S-TRAC despite immature OS data. Additional analyses across completed trials are warranted to further assess the relationship between DFS and OS.
Clinical trial identification
NCT00375674.
Legal entity responsible for the study
Pfizer.
Funding
Pfizer.
Editorial Acknowledgement
Editorial support was provided by Vardit Dror, PhD, of Engage Scientific Solutions, and funded by Pfizer.
Disclosure
D.J. George: Honoraria and consulting: Sanofi, Exelixis, Bayer; Consulting: Merck, Sanofi; Grants: Genentech/Roche, Novartis, Astellas, Celldex, Acerta; Grants & consulting: Exelixis, Janssen, Pfizer, Innocrin Pharma, BMS. A.J. Pantuck: Consulting fees: Pfizer. R. Figlin: Research funding: Peloton, BMS, Argos Therapeutics, Exilexis, and Cerulean; Consulting fees: Novartis, Pfizer, Nektar, Peloton, Calithera, Acceleron. B. Escudier: Consulting fees: Bayer, Pfizer, Novartis; Honoraria: Bayer, Roche, Pfizer, Genentech, Novartis, Aveo. S. Halabi: Data and Safety Monitoring Board member: Eisai. M. Casey, X. Lin, L. Serfass, M.J. Lechuga Frean: Employee of and own stock in Pfizer. A. Ravaud: Advisory boards: Pfizer, Novartis, GSK, Roche, BMS; Institutional support grants: Pfizer, Novartis; Housing and transportation for meetings and speeches: Pfizer, Novartis, BMS.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract